Merck Serono combines its complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) to offer innovative prescription drugs of either origin.
With comprehensive skills in all areas from research and development to manufacturing, marketing and sales, the division offers its world-class products in over 150 countries worldwide. Our strategically positioned workforce of 8,000 sales and marketing employees ensures commercial coverage in the U.S. and Canada, Latin America, Europe, Asia-Pacific and Japan.
The division has leading brands serving patients in its therapeutic areas of focus:
Oncology – Erbitux®, UFT®
Merck Serono focuses on developing novel, cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients. Our monoclonal antibody, Erbitux, specifically blocks the epidermal growth factor receptor (EGFR) to enhance the effect of chemotherapy and radiotherapy.
Neurodegenerative diseases – Rebif®, Novantrone®
Merck Serono is a market leader in the treatment of Multiple Sclerosis (MS) with Rebif®, approved for the treatment of relapsing-remitting MS in over 80 countries worldwide. In the United States, we market Novantrone® for worsening forms of MS.
Fertility – GONAL-f®, Ovidrel, Luveris®, Cetrotide®, Crinone®, Pergoveris®
Merck Serono is the world leader in fertility treatment. We offer a broad portfolio of gonadotropin hormones for the treatment of infertility at different stages of the reproductive cycle, allowing physicians to tailor treatment to individual patient needs.
Endocrinology – Saizen®, Serostim®
Merck Serono was a pioneer in making recombinant growth hormone available for the treatment of growth hormone deficiency in children and adults (Saizen) and for the treatment of HIV-associated wasting (Serostim).
CardioMetabolic Care – Glucophage®, Concor®, Euthyrox®
Merck Serono offers an extensive range of therapeutic options for the integrated management of cardiovascular and metabolic diseases. These include the Glucophage franchise of oral antidiabetics for the treatment of type 2 diabetes, the beta-blocker bisoprolol (Concor) and a range of thyroid hormones (Euthyrox).
New Specialist Therapies: Psoriasis - Raptiva®
Merck Serono is committed to developing innovative treatments for patients with unmet medical needs. Raptiva® (efalizumab), a novel humanized therapeutic antibody, is a new type of treatment that offers hope for patients with psoriasis, a chronic inflammatory skin disease.